A Pilot Study of Influenza Vaccine Efficacy in Patients With Central Nervous System Tumors
18 Years
N/A
Both
Central Nervous System Neoplasm
Trial Information
A Pilot Study of Influenza Vaccine Efficacy in Patients With Central Nervous System Tumors
PRIMARY OBJECTIVES:
I. The primary objective of this pilot study is to assess the efficacy of influenza
vaccination in patients with central nervous system tumors as defined by a four-fold
increase in hemagglutinin inhibition (HI) titers from the pre-vaccination baseline.
SECONDARY OBJECTIVES:
I. A secondary objective of this pilot study is to assess the efficacy of influenza
vaccination in patients with central nervous system tumors as defined by a serum
post-vaccination HI titer of at least 1:40.
II. The secondary objectives of this pilot study include an assessment of the relationship
between a variety of clinical factors and seroconversion following influenza vaccination.
III. Subgroup analyses will include an investigation of seroconversion and treatment
(actively receiving chemotherapy, radiation therapy or both), disease status (active
treatment vs long term followup), and use and dose of glucocorticoids.
TERTIARY OBJECTIVES:
I. An additional area of interest which will be further explored in this pilot study is an
assessment of the relationship between serologic markers of immune function and response to
vaccination.
OUTLINE:
Patients receive trivalent influenza vaccine intramuscularly (IM) on day 0.
After completion of study treatment, patients are followed up at 14 days, 21 days, and 3
and/or 6 months.
Inclusion Criteria:
- Patients must have a clinical diagnosis of a primary central nervous system tumor
- Patients must be eligible to receive the influenza vaccine
- Patients must be able to provide written informed consent
Exclusion Criteria:
- Patients unable to receive the influenza vaccine due to history of allergy to egg
proteins, allergy to influenza vaccine component, acute febrile illness at the time
of proposed vaccine administration, history of clinically or virologically confirmed
influenza infection in the previous 6 months, contraindication to intramuscular
injections, Guillan-Barré syndrome, or other contraindication to the vaccine
- Patients who have received the 2011-2012 annual influenza vaccine prior to being
considered for enrollment on this study
Type of Study:
Interventional
Study Design:
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Outcome Measure:
Efficacy of influenza vaccination in patients with central nervous system tumors as defined by a four-fold increase in HI titers from the pre-vaccination baseline
Outcome Description:
Seroconversion rate will be defined as the percentage of patients with at least a four-fold increase in HI antibodies between baseline and follow up. Seroprotection rate will be defined as the percentage of patients with a serum HI antibody of at least 1:40. The relationship between seroconversion and various clinical variables including therapy status (active vs longterm follow-up), glucorticoid dose and immune function will be measured. Seroconversion and seroprotection rate comparisons will be made to publish normative data for the general population.
Outcome Time Frame:
6 months
Safety Issue:
No
Principal Investigator
Glenn Lesser
Investigator Role:
Principal Investigator
Investigator Affiliation:
Wake Forest University
Authority:
United States: Institutional Review Board
Study ID:
CCCWFU 98411
NCT ID:
NCT01474174
Start Date:
September 2011
Completion Date:
Related Keywords:
- Central Nervous System Neoplasm
- Neoplasms
- Influenza, Human
- Nervous System Neoplasms
- Central Nervous System Neoplasms
Name | Location |
|---|---|
| Wake Forest University Health Sciences | Winston-Salem, North Carolina 27157 |
